Navigation Links
Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma
Date:1/7/2009

statements are based on the companies' managements' current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward- looking statements as a result of many factors, including, without limitation, failure of Nuvelo's stockholders to approve the proposal regarding the reverse stock split, the ability to complete the transaction contemplated by this communication in a timely fashion, the risk that Nuvelo's and ARCA's business operations will not be integrated successfully; the combined company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the combined company's financial resources will be insufficient to meet the combined company's business objectives; uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in the companies' clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10-Q for the quarter ended September 30, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.

Additional Information and Where to Find It

Nuvelo has filed a registration statement on Form S-4, and a related proxy statement/prospectus/consent solicitation, in connection with the merger. Investors and security holders are urged to read the registration statement on Form S-4 and the related proxy statement/prospectus/consent solicitation because they contain important information about the merger trans
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
4. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
5. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
6. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
9. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
10. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
11. Pharmos Issues Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... Arthur Kay , the 23-year-old British founder of environmentally ... Challenge 2014. The jury, chaired by Ellen MacArthur ... final in Amsterdam to realize ... uses a patented process to upcycle waste coffee grounds ... used for powering buildings and transport systems. Bio-bean is ...
(Date:9/12/2014)... LONDON , September 12, 2014 ... 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the ... at 1,997.45, up 0.09%. The gains were broad based as ... The S&P 500 Health Care Sector Index ended the day ... in the last one month. Investor-Edge has initiated coverage on ...
(Date:9/11/2014)... team of Berkeley Lab researchers believes it has ... of single atomic layers of transition metal dichalcogenide ... promise for nanoelectronic and photonic applications. , ... of tungsten disulfide, one of the most promising ... existence of excitonic dark states energy states ...
(Date:9/11/2014)... -- XBiotech announced today it has taken delivery on ... says will be used to dramatically increase its fill ... fill, stopper and crimp vials, which is the final ... said to contain an in-line feed back loop and ... of quality compared to less sophisticated filling systems. The ...
Breaking Biology Technology:Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3
... Enanta Pharmaceuticals, Inc. announced today that its lead ... inhibitor program, EDP-239, has been recognized on Windhover,s list ... to Watch." EDP-239 was chosen by independent experts at ... a clinically-validated target, is a non-structural viral protein that ...
... at deCODE Genetics and academic collaborators from Iceland, The Netherlands, ... today report the discovery of a variant in the sequence ... cell carcinoma of the skin (BCC), as well as prostate ...  The study was done in collaboration with Illumina, Inc., and ...
... Sept. 23, 2011 Citizens Bank today announced that ... a major expansion by The Wistar Institute that includes ... historic facility at 36th and Spruce streets in University ... an international leader in basic biomedical research, particularly cancer ...
Cached Biology Technology:Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch 2Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch 3deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers 2deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers 3Citizens Bank Provides $70 Million in Financing Toward $100 Million Expansion of The Wistar Institute 2
(Date:9/12/2014)... come under attack from a pathogen, they sometimes respond ... the attack, committing "cell suicide" to thwart further damage ... small, often microscopic, spots or lesions on the plant. ... understand how the plant regulates this "spotty" defense mechanism ... Researchers at North Carolina State University have identified a ...
(Date:9/12/2014)... and POINT ROBERTS, Washington , September 12, ... http://www.investorideas.com ) a global news source covering leading sectors including ... on the September 9 th launch of Apple Pay, ... Intelligence, Janice Kephart , founder of the Secure Identity ... of NXT-ID, Inc, (NASDAQ: NXTD ) a company ...
(Date:9/11/2014)... Amsterdam, NL, 11 September 2014 Patients with ... preparation and ingestion, which could contribute to poor ... Published studies have also suggested that PD is ... control groups. A report published in the ... in patients with mild-to-moderate PD, finding that the ...
Breaking Biology News(10 mins):Corn spots: Study finds important genes in defense response 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 3Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 5Few mild-to-moderate Parkinson's disease patients suffer from malnutrition, yet almost one-third are at risk 2
... Study of Hepatitis C (PEDS-C) trial reveals that children ... display significant changes in height, weight, body mass index ... issue of Hepatology , a journal of the ... that most growth-related side effects are reversible with cessation ...
... New Rochelle, NY, August 9, 2012Despite criticism from Congressional ... its Rim of the Pacific (RIMPAC) 2012 international maritime ... 50% biofuels blend. The Navy contends that renewable energy ... play in enhancing national security and energy independence. Tom ...
... University researchers are teaming up with Coastal Carolina University ... along the Savannah River to gather data for the ... and transmit real-time information about the quality and quantity ... project leaders Gene Eidson, director of Clemson,s Institute of ...
Cached Biology News:Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C 2US Navy defends renewable fuels strategy in Industrial Biotechnology Journal 2Clemson, Coastal Carolina universities to set hundreds of sensors in Savannah River 2
Mouse monoclonal antibody to UGT2B10 - UDP glucuronosyltransferase 2 family, polypeptide B10...
... cleanup kit is a sample preparation kit ... by removal of detergents, phenolic compounds, salts, ... concentrates dilute samples. The kit procedure involves ... mammalian tissue or cells, plant leaves, E. ...
... XIII in both reduced and non-reduced forms. It ... or human Factor XII. Factor XIII is a ... two subunits. Factor XIII-A is the catalytic subunit ... XIII is present in plasma as an Alpha2Beta2 ...
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Biology Products: